| Revenue growth | Revenue +35% YoY to ₹538 Cr; licensing income boost unquantified. |
|---|---|
| Margins | EBITDA margin 28% in Q2; gross margin down ~700 bps YoY. |
| Demand visibility | Peptide demand based on customer indications; no firm orders in hand. |
| Management confidence | Overly optimistic; CEO bullish, CFO deflects forward-looking questions. |
Growth
Revenue +35% YoY to ₹538 Cr; H1 ₹1,007 Cr (+44%). Formulation +50%+, ex-licensing base +87%; licensing share undisclosed.
Outlook
No forward guidance given. Peptide utilisation comment deferred to next year's H2. No albumin revenue guidance.
Risks
Gross margin down ~700 bps on API mix and raw material costs. Licensing share undisclosed. US FDA remediation at a plant.
Last quarter's promises, checked
Partly delivered
- Guided EBITDA margin around 30%, 'similar range' → delivered 28% (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹923.00
- Market cap
- ₹18,052 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 54.3×Sector 37.9×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 12.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Insolvency Petition
Shilpa Medicare reports NCLAT set aside the CIRP against its subsidiary FTF Pharma, annulling the process. The filing states no impact on the listed entity.
Shilpa Medicare Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 538 cr (+45% YoY), EBITDA INR 151 cr (28% margin), PAT INR 79 cr (+80%). 1HFY27 total income INR 1,007 cr (+44%). Strategy: complex FDF launches, CDMO, biologics, rHA.
Shilpa Medicare Q2 FY27 Results: Net Profit ₹79.2 Cr, Up 79.6% YoY
Shilpa Medicare Ltd reported revenue from operations of ₹529.1 Cr (+43.0% YoY) and net profit of ₹79.2 Cr (+79.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹79.2 Cr · +79.6% YoY
Shilpa Medicare Board Meeting Date
Shilpa Medicare's board meeting is scheduled for 5 November 2026 to approve Q2 and H1 unaudited financial results. The trading window remains closed until 7 November 2026.
Shilpa Medicare Business Update
Shilpa Medicare Limited’s Unit 4 in Jadcherla received GMP certification from AGES, Austria, following a successful inspection. This milestone enables operations for European and global markets.
Shilpa Medicare Other Announcement
Shilpa Medicare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.